



DEEPVESSEL® FFR

CT-FFR Analysis with DEEPVESSEL FFR

FDA-cleared, CE-marked, NMPA-approved, and HSA-approved


DEEPVESSEL FFR (DVFFR) is a software medical device that uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using CCTA. The software processes CCTA images semi-automatically, of the derived information is sent electronically to physicians. DEEPVESSEL FFR is intended to support the functional evaluation of CAD. DEEPVESSEL FFR applies Keya Medical’s proprietary deep learning technologies built on the latest advances in computer vision and medical image analysis.

The 2021 ACC and AHA Guidelines for the Evaluation and Diagnosis of Chest Pain highlight the use of Coronary CTA + FFR CT as a front-line pathway¹.




AFFORDABLE	ACCURATE	ACCESSIBLE	EFFICIENT	COMPREHENSIVE
Offers pricing options tailored to the payment capabilities of patients and payers.	Achieves high diagnostic accuracy using invasive FFR as the ground truth	Delivers web-based results accessible on PCs and smart devices	Provides rapid results for timely decision-making	Calculates FFR values at any location in the coronary tree

Intelrad Ambra Imaging Platform Workflow



DEEPVESSEL FFR Customers



Diagnostic Performance: Multi-national, multi-center clinical validation study ADAPT²

Per-Vessel	Estimate, %	One-Sided 95% CI (lower bound)	Target Rate	Met/Not Met
Sensitivity	86.9%	80.6%	75%	Met
Specificity	86.7%	82.0%	70%	Met
Accuracy	86.8% (82.5%-90.4%)			

Per-Patient	Estimate, %	Two-Sided 95% CI
Sensitivity	87.4%	79.4%–93.1%
Specificity	83.7%	76.5%–89.4%
Accuracy	85.2%	80.2%–89.4%

1 Gulati, et al. 2021 AHA/ACC/ASE/CHES/SAEM/SCCT/SCMR Guideline for the Evaluation & Diagnosis of Chest Pain. Circulation.
 2. <https://clinicaltrials.gov/ct2/show/NCT04828590>